{"id":"NCT02985398","sponsor":"Alder Biopharmaceuticals, Inc.","briefTitle":"An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine","officialTitle":"An Open Label Phase 3 Trial to Evaluate the Safety of ALD403 Administered Intravenously in Patients With Chronic Migraines","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-12","primaryCompletion":"2018-04","completion":"2019-03","firstPosted":"2016-12-07","resultsPosted":"2020-04-21","lastUpdate":"2020-04-21"},"enrollment":128,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Migraine Disorder"],"interventions":[{"type":"BIOLOGICAL","name":"ALD403 (Eptinezumab)","otherNames":["Eptinezumab-jjmr","Vyepti"]}],"arms":[{"label":"ALD403 (Eptinezumab) Dose Level 1","type":"EXPERIMENTAL"}],"summary":"An evaluation of long term safety of repeat ALD403 doses in Chronic Migraine","primaryOutcome":{"measure":"Number of Participants With Any Treatment Emergent Adverse Events (TEAEs)","timeFrame":"104 Weeks","effectByArm":[{"arm":"300 mg ALD403","deltaMin":91,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":4},"locations":{"siteCount":20,"countries":["United States"]},"refs":{"pmids":["35804294","33781209","33740902"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":128},"commonTop":["Nasopharyngitis","Sinusitis","Upper respiratory tract infection","Influenza","Bronchitis"]}}